TEVA PHARMACEUTICAL INDUSTRIES LTD
Form 6-K
September 25, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a 16 or 15d 16 under the Securities Exchange Act of 1934

For the month of September 2008

Commission File Number ______0-16174

__1__

Teva Pharmaceutical Industries Limited
(Translation of registrant's name into English)
5 Basel Street, P.O. Box 3190
Petach Tikva 49131 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
Yes NoX
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b):
82

<u>om</u>

www.tevapharm.c
September 25, 2008
NOTICE
At the Special Meeting of Shareholders of Teva Pharmaceutical Industries Ltd. held on September 25, 2008, the resolution on the agenda to appoint Mr. Joseph (Yosi) Nitzani as a statutory independent director for a term of three years, was approved by the shareholders.
Teva Pharmaceutical Industries Ltd.

__2__

Edgar Filing: TEVA PHARMAC	CEUTICAL INDUSTRIES LTD - Form 6-K
Teva Pharmaceutical Industries Ltd.	Web Site: www.tevapharm.com
SI	IGNATURES
Pursuant to the requirements of the Securities Exchan signed on its behalf by the undersigned, thereunto dul	nge Act of 1934, the registrant has duly caused this report to be ly authorized.
TEVA PHARMACEUTICAL INDUSTRIES LIMITI (Registrant)	ED
By: <u>/s/ Eyal Desheh</u>	
Name: Eyal Desheh Title: Chief Financial Officer	

Date: September 25, 2008

3